ADV Research ADV-11 (YK-11 SARM Alternative) All orders will be dispatched on Friday June 15th. KEY BENEFITS Powerful experimental myostatin inhibitor Potentially promotes lean muscle growth and increase lean body mass Potentially helps build on your genetic potential Potentially stimulates hair regrowth Potentially no negative impact on prostate size GENDER SUITABILITY ADV-11 may be suitable for use by both males…
If you are interested in order a product you will need to fill out our quick 2-minute Medical Questionnaire. As we provide Schedule 4 medication we require your medical details so our Prescribing Doctor can provide you with the safest and most effective solution for your health and fitness goals. If you have any further questions surrounding our Order Process please feel free to call out Customer Support team to discuss any concerns.
by Bill Roberts – GHRP-6 is an injectable peptide in the category of growth hormone releasing peptides, or GHRP’s. The most common use of these peptides is to increase GH production. Other peptides in this category include GHRP-2, hexarelin, and ipamorelin. With regard to increasing GH, all of these work similarly, and there is no need or advantage to combining them. Instead, the one most suited for the particular case is chosen.
An intact hypothalamic-pituitary axis is required to achieve the maximal effect of GHSs on GH release. GHRH and somatostatin both influence the action of GHSs, augmenting and diminishing the magnitude of the GH pulse, respectively. When GHRH is administered in combination with GHSs, the effect is synergistic, the magnitude of the GH pulse being greater than that obtained from the sum of the two agents administered separately. GHS stimulation of GH secretion requires the presence of GHRH. In members of a family with a homozygous inactivating mutation of the GHRH receptor, hexarelin was ineffective in stimulating GH release. In addition, children who are GH-deficient as a result of pituitary stalk transsection are unresponsive to GHSs. Thus, somatotroph exposure to GHRH is necessary for GHSs to exert their action.
Consistent with these data, our group observed a transient inotropic effect of about 15 minutes in both healthy and infarcted rabbits following a single GHRP-6 intravenous bolus (400 µg/kg). Echocardiography recordings indicated a 15%–20% elevation of the ejection fraction as an increase in shortening fraction (Juan Valiente Mustelier and Jorge Berlanga Acosta, unpublished observations, 2007). More recent studies based on isolated murine hearts that underwent periods of ischemia and reperfusion (I/R) confirm that pre- or posttreatments with hexarelin for instance prevented the intracellular disturbances in Ca+2 transients through recovery of p-PLB after the I/R insult.43 Other studies involving adult Wistar rat ventricular myocytes have confirmed the positive inotropic response induced by hexarelin and other secretagogue peptides that bind the GHS-R1a, which activates protein kinase C signaling cascade.44
Aging often comes with many undesirable effects on our bodies including increased fat, decreased muscle muscle mass and low energy. Some of these issues can be caused by adult growth hormone deficiency. Peptide therapies provide a healthy option to reinvigorate the natural release of growth hormone in the body and reverse the negative effects of aging.
Biokey Research TESTO-MAX 20 BRAND: TESTOLONE (RAD140) TESTOLONE (RAD140) Purity : 100% Molecular Formula : C20H16ClN5O2 Molecular Weight: 393.831 CAS#: 1182367-47-0 Description: RAD140 Testolone 30ml @ 20mg per ml Recommended dosage: 0.5-1ml daily DESCRIPTION TESTO-MAX 20 by BioKey Research boasts 20mg/ml of RAD140 which was medically designed to replace testosterone allowing the body to react the same way it would to a healthy dose of the hormone less the…
Growth hormone (GH) was first identified for its notable effect on longitudinal growth. Subsequent research revealed that the GH has anabolic effects on protein, lipid, and carbohydrate metabolism. GH replacement therapy, using recombinant GH, is therefore used to treat individuals with short stature due to a variety of conditions. However, GH replacement therapy suffers from significant drawbacks such as low bioavailability and side effects. Moreover, most GH-deficient individuals exhibit a secretory defect rather than a primary deficiency in GH production. Research seeking a better drug to replace GH was therefore extensively active in the 1980s and 1990s.
Total RNA was purified according to TRI Reagent standard procedure (Sigma, USA), following digestion with RQ1 DNase I (Promega, USA) to remove contaminating genomic DNA. Afterward, 500 ng of DNA-free RNA was reverse transcribed using Omniscript RT kit (Qiagen, Germany) with oligo-dT primer. The RT reaction was performed at 42°C for 60 min. PCR mixtures contained 1 μL cDNA, 1 μL of each primer (10 μM), and 12.5 μL 2x Taq MasterMix (Qiagen, Germany) in a final volume of 25 μL. Specific sense and antisense primers, annealing temperatures, and number of repeating cycles for both studies are referred to in Table 1. Amplifying conditions were performed as follows: a first step of 95°C for 5 minutes, thereafter repeating cycles comprised of 95°C for 30 seconds, specific annealing temperature for 30 seconds and 72°C for 30 seconds, and a final extension step of 5 minutes at 72°C. PCR bands (8 μL of PCR product plus 2 μL of gel loading buffer) were resolved on 1.5% (w/v) agarose gel electrophoresis and visualized under ultraviolet light subsequent to being stained with ethidium bromide. PCR products were quantified using the Kodak ID 3.6 software package (Kodak Inc, USA). Beta-2 microglobulin was used as housekeeping gene for normalization.
Now you can use advanced D.N.A. enhancement which is beyond anabolic steroids! Learn about the one or two course of peptides anyone can get and make a change in the make up of your genetic blueprint for life. Unlike chemical enhancements, which require regular injections or oral administration to have a continued effect. Peptides specific to the system you are trying to enhance are availible now. Without any side effects unlike anabolic steroids.
In June 2003, the NDPSC decided to reschedule mometasone from Schedule 3 to Schedule 2 for the short-term prophylaxis or treatment of allergic rhinitis, with dose and age restrictions. The NDPSC considered that this rescheduling was appropriate given mometason's extensive local and overseas experience, demonstrated effectiveness in the treatment of allergic rhinitis and that allergic rhinitis is readily diagnosed and self-monitored by the consumer with pharmacist advice or counselling available if necessary. As there would no longer be a Schedule 3 entry, the NDPSC also decided to delete mometasone from Appendix H.
As the name indicates, this peptide is a fragment of human growth hormone. It is more specifically a modified form of the amino acids 176-191 in the C-terminal section of the latter substance. Bodybuilders mainly use it enhance fat burning for improved and more noticeable muscle growth. For weight loss, HGH Fragment 176-191 is thought to be considerably more potent than regular growth hormone. It also offers anti-aging benefits as a result of positive effects on IGF-1 levels.
In June 2007, the NDPSC decided to extend the exemption from the limit on paracetamol combinations being allowed as general sale products to include phenylephrine (as long as it also qualified as exempt from scheduling through the phenylephrine entries). At that time, the NDPSC considered that the safety profile of these substances was such that allowing a fixed combination to be unscheduled was reasonable.
Peptides are short chain amino acid monomers linked by a peptide bond. The body utilizes these short amino acids chains to secrete/pulse growth hormone (GH) that is already stored in your body. This is a very attractive option for those who are not able to utilize synthetic human growth hormone (HGH) naturally. In fact, this could even be a safer alternative for those seeking to use growth hormone for recovery, anti-aging and fat-loss. There are a multitude of peptides on the market and new ones being created almost monthly. Therefore, for the sake of an overview, let me just touch upon the ones that are most commonly used. To begin, let me start by first breaking down the two most important peptide groups for bodybuilding.
Dosing will ordinarily be at least twice per day and preferably 3x/day for best effect, taken at least 30-60 minutes before a meal and at a time of non-elevated blood sugar (in other words, after blood sugar has had time to fall since the most recent meal.) The amount taken generally will be from 50-300 mcg at a time. When using a GHRH along with GHRP-6, dosing should be reduced to 50-100 mcg at a time.
GHRH (Growth Hormone Releasing Hormones) cause the body to secrete a small amount of growth hormone. Depending upon the peptide, there can be short to long secreting times. Also, be aware that with most peptides there is a saturation dose (normally around 100mcg at a time). This means that going beyond the saturation dose will not produce an increase in growth hormone release. Experienced peptide users have indicated that saturation doses may actually be higher than 100mcg. However, this seems to depend on the purity of the peptides, and perhaps even based on the individual person themselves. In general, due to the nature of peptides, a lot of information has become anecdotal in nature rather than scientific.
Similar to GHRP 2, this peptide is a more potent releaser of growth hormone, also acting on the ghrelin receptors of the anterior pituitary. Also like GHRP 2, GHRP 6 leads to increased growth hormone production, increased lead body mass, and decreased adiposity. Due to the peptide’s ghrelin-like properties, administration can lead to increased appetite.
* Post script note: The expression "too restrictive to dental practitioners in the exercise of their professional practice" is a comment on the scope of the SUSMP to place controls on the activities of professional practitioners. The location of use of a chemical substance, whether by a registered practitioner in-clinic or by an individual consumer at home, is not intended to be controlled through the SUSMP. Limitations on the location of use would be applied through the policies of professional practice boards (i.e. the Dental Board of Australia) or other relevant regulatory authorities (including the Australian Competition and Consumer Commission).
Ipamorelin is very similar to the growth hormone releasing peptides (GHRPs) GHRP 2 and GHRP 6 in that it mimics ghrelin (the hunger hormone) and targets a specific HGH pulse. However, unlike other GHRPs, this peptide doesn’t affect the release of cortisol, acetylcholine, prolactin and aldosterone thereby minimizing side effects experienced with other GH therapies, such as increased hunger. Because there are virtually no negative side effects, Ipamorelin can be prescribed more aggressively and more frequently than other therapies without the risk of elevated cortisol and acetylcholine blood plasma levels. This helps optimize HGH levels for a longer period of time, leading to more successful health outcomes.
TO-2 hamster model of DCM was characterized by progressive LV dilation, LV wall thinning, LV systolic dysfunction, and reduced life span; both GHRP-2 and GHRP-6 ameliorated all the dysfunctional ventricular parameters and reduced the progression of the DCM.34 We also examined the potential impact of GHRP-6 in a rat model of DCM/heart failure induced by doxorubicin (DX). The concurrent administration of GHRP-6 was undertaken with the purpose to study the potential prophylactic impact before the cardiac function demise. As part of the prolonged treatment with DX, the concurrent administration of GHRP-6 completely prevented failure of cardiac function, which was evaluated as the percentage of ejection fraction by echocardiography (Figure 2, prevention). This effect significantly increased the survival of animals. Similar results were obtained in the therapeutic administration schedule, with functional recovery of cardiac muscle to physiological levels (Figure 2, regression), also attenuating systemic damages and, consequently, decreasing the mortality rates of rats. In the experimental model of DX-induced cardiac and systemic damage, GHRP-6 additionally attenuated various extracardiac damages observed in the renal tubular and bronchoalveolar epithelial structures as in the hepatic parenchyma.35
From the examination of many studies, the saturation GHRP-6 doses have been determined to be 1mcg per kg of body weight, and an average dose of approximately 100mcg without concern for bodyweight   . That is to say that a 100mcg saturation dose of GHRP-6 will fully saturate receptors, and that 200mcg will only provide 50% additional effectiveness, and a 300mcg dose will provide only 25% additional effectiveness, and so on and so forth. This is very much the case with almost all GHRPs and GHRH analogues, as it seems to be the nature of these peptides.
If GHRP-6 is powerful for growth hormone release, this peptide is even stronger, albeit slightly so. GHRP-2 is used for similar purposes as the other compound. But it does not fire up appetite as the other peptide is known to do. This may make it more ideal for people interested in improving lean muscle mass. Furthermore, it does not desensitize when taken in low doses without observing breaks as required for other peptides.
for teeth whitening products containing between 3 per cent to 6 per cent of hydrogen peroxide and between 9 per cent to 18 per cent of carbamide peroxide to be only legally accessible from a registered health practitioner. Patients to be permitted to use these products 'at home' only after consultation with their registered health practitioner; and
MuscleSport PCT Revolution ADVANCED POST-CYCLE THERAPY PCT Revolution should be used after the use of any SARM. This ensures natural testosterone production increases and excess estrogen production is reduced. When your body produces abnormally high levels of testosterone for an extensive period of time you need to get your system back firing on all cylinders. Post-Cycle Therapy does just that.…
Conclusions: Subcutaneous administration of CJC 1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 ug/ kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC 1295 as a therapeutic agent.
During the last 15 years, a plethora of experimental evidence supports the pharmacological benefits of the exogenous administration of synthetic growth hormone-releasing peptides (GHRPs). In parallel to their growth hormone-releasing action, these agents exert cytoprotective effects encompassing cardiac and extracardiac organs . GHRP-6 is a class of peptidyl GH secretagogue, similar to met-enkephalin, that has reproducibly shown antinecrogenic and antiapoptotic properties in multiple experimental scenarios, including ischemia/reperfusion [9–11]. Globally speaking, exogenously administered GHRP-6 has broadly been shown to act as a prosurvival factor for cells and tissues threatened by otherwise lethal insults.
Without going into great detail, think of GHRP’s as targeting a pulse when you want it; meaning, once you take it, you get a burst of GH. On the other hand, with GHRH’s you really have to time when your body will have its own pulse to get the most out of administering them. In simple terms, if you use GHRH's at the wrong time, the results are minimal.
As judged by the PubMed outcomes, the cytoprotective effects of synthetic peptidyl GHRP appear far less studied in noncardiac, parenchymal epithelial organs or multiple organ systems than in the cardiovascular system. However, the results of the reviewed studies are consistent with a broad cytoprotective influence for various organs by reducing inflammation and preventing necrosis and/or apoptosis. The mechanism of GHRP-mediated pharmacological actions is shown in Figure 4.
In extracardiac models of striated muscles atrophy, GHRP-2 exerted a potent myoprotective effect, presumably via the direct agonistic stimulation of the GHS-R1a since no elevation of IGF-1 transcript was observed.49 Thus, it is likely that GHRP cardioprotective effects in scenarios of DCM may be somehow mediated by a trophic or anabolic mechanism. Based on the benefits of GHRP-6 on muscle functions, a newly synthesized GHRP-6-biotin conjugate tested on cultured myoblasts showed that it induced the expression of myogenic proteins and IGF-1 levels similar to the concentrations of energy metabolites and the corresponding enzymes. Practical applications of the GHRP-6-biotin conjugate could include amelioration of sarcopenia and/or cardiac cachexia.50
After repeated intravenous (i.v.) boluses of growth hormone-releasing peptide-6 (GHRP-6) we found recently increases of growth hormone (GH), corticotropin (ACTH) and cortisol levels and of the amount of stage 2 sleep. In clinical use, oral (p.o.), intranasal (i.n.) and sublingual (s.l.) routes of administration have advantages over i.v. administration. We compared the sleep-endocrine effects of 300 microg/kg of body weight (b.w.) GHRP-6 in enteric-coated capsules given p.o. at 21.00 h and of 30 microg/kg GHRP-6 i.n. or 30 microg/kg GHRP-6 sl. given at 22.45 h in normal young male controls with placebo conditions. After GHRP-6 p.o. secretion of GH, ACTH and cortisol remained unchanged. The only effect of GHRP-6 s.l. was a trend toward an increase in GH in the first half of the night. GHRP-6 i.n. prompted a significant increase in GH concentration during the total night and a trend toward an increase in ACTH secretion during the first half of the night, whereas cortisol secretion remained unchanged. Furthermore, after GHRP-6 i.n., sleep stage 2 increased in the second half of the night by trend, and spectral analysis of total night non-rapid eye movement (REM) sleep revealed a decrease of delta power by trend. In contrast sleep stage 2 decreased during the second half of the night after GHRP-6 p.o. Our data demonstrate that GHRP-6 is capable of modulating GH and ACTH secretion as well as sleep. However, the effects depend upon dosage, duration and route of administration.